^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Published date:
05/04/2021
Excerpt:
Response assessments included five complete and 15 partial responses, making the irRECIST RR 29% among the entire trial population...The median progression-free survival was 5.0 months, and the median overall survival was 24.7 months...Responses occurred in PD-L1–negative....prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
DOI:
10.1200/JCO.21.00079
Trial ID:
